Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
Open Access
- 6 July 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-16
Abstract
Infiltration into lymphatic vessels is a critical step in breast cancer metastasis. Lymphatics undergo changes that facilitate metastasis as a result of activation of the cells lining lymphatic vessels, lymphatic endothelial cells (LECs). Inhibition of activation by targeting VEGFR3 can reduce invasion toward lymphatics. To best benefit patients, this approach should be coupled with standard of care that slows tumor growth, such as chemotherapy. Little is known about how chemotherapies, like docetaxel, may influence lymphatics and conversely, how lymphatics can alter responses to therapy. A novel 3D in vitro co-culture model of the human breast tumor microenvironment was employed to examine the contribution of LECs to tumor invasion and viability with docetaxel and anti-VEGFR3, using three cell lines, MDA-MB-231, HCC38, and HCC1806. In vivo, the 4T1 mouse model of breast carcinoma was used to examine the efficacy of combinatorial therapy with docetaxel and anti-VEGFR3 on lymph node metastasis and tumor growth. Lymphangiogenesis in these mice was analyzed by immunohistochemistry and flow cytometry. Luminex analysis was used to measure expression of lymphangiogenic cytokines. In vitro, tumor cell invasion significantly increased with docetaxel when LECs were present; this effect was attenuated by inhibition of VEGFR3. LECs reduced docetaxel-induced cell death independent of VEGFR3. In vivo, docetaxel significantly increased breast cancer metastasis to the lymph node. Docetaxel and anti-VEGFR3 combination therapy reduced lymph node and lung metastasis in 4T1 and synergized to reduce tumor growth. Docetaxel induced VEGFR3-dependent vessel enlargement, lymphangiogenesis, and expansion of the LEC population in the peritumoral microenvironment, but not tumor-free stroma. Docetaxel caused an upregulation in pro-lymphangiogenic factors including VEGFC and TNF-α in the tumor microenvironment in vivo. Here we present a counter-therapeutic effect of docetaxel chemotherapy that triggers cancer cells to elicit lymphangiogenesis. In turn, lymphatics reduce cancer response to docetaxel by altering the cytokine milieu in breast cancer. These changes lead to an increase in tumor cell invasion and survival under docetaxel treatment, ultimately reducing docetaxel efficacy. These docetaxel-induced effects can be mitigated by anti-VEGFR3 therapy, resulting in a synergism between these treatments that reduces tumor growth and metastasis.Keywords
Funding Information
- Kincaid Foundation
- University of Virginia Cancer Center
- National Institutes of Health (NIH 5T32 GM008715, NIH T32 CA 009109)
This publication has 73 references indexed in Scilit:
- TLR4 Promotes Breast Cancer Metastasis via Akt/GSK3β/β‐Catenin Pathway upon LPS StimulationThe Anatomical Record, 2017
- Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohortBreast Cancer Research and Treatment, 2015
- Cancer-mediated adipose reversion promotes cancer cell migration via IL-6 and MCP-1Breast Cancer Research and Treatment, 2015
- Tumor location and nature of lymphatic vessels are key determinants of cancer metastasisClinical & Experimental Metastasis, 2012
- Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to ResistanceCancer Cell, 2012
- Lymphatic endothelial cell‐secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancerInternational Journal of Cancer, 2011
- Autologous Chemotaxis as a Mechanism of Tumor Cell Homing to Lymphatics via Interstitial Flow and Autocrine CCR7 SignalingCancer Cell, 2007
- Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphaticsCancer and Metastasis Reviews, 2006
- INDUCTION OF PROINFLAMMATORY AND CHEMOKINE GENES BY LIPOPOLYSACCHARIDE AND PACLITAXEL (Taxol™) IN MURINE AND HUMAN BREAST CANCER CELL LINESCytokine, 2001
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agentsBioEssays, 1991